Is GoHealth, Inc. overvalued or undervalued?

As of 7 August 2025, the valuation grade for GoHealth, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. Based on the current metrics, the company appears to be overvalued. Key ratios include a P/E ratio of 6, an EV to EBITDA of 0.44, and a PEG ratio of 0.05, all of which suggest that the stock is not priced in line with its earnings growth potential.
In comparison to peers, GoHealth's P/E ratio of 2.12 is significantly lower than Crawford & Co.'s fair valuation P/E of 17.88, highlighting a stark contrast in market perception. Additionally, GoHealth's EV to EBITDA ratio of 0.418 is also less favorable compared to its peers. The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -63.7% compared to the index's 12.22%, reinforcing the notion that GoHealth is currently overvalued.